Presentation is loading. Please wait.

Presentation is loading. Please wait.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

Published byἈρίσταρχος Ασπάσιος Modified over 5 years ago

Similar presentations

Presentation on theme: "Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational."— Presentation transcript:

1 Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])  Bruce E. Strober, MD, PhD, Robert Bissonnette, MD, David Fiorentino, MD, PhD, Alexa B. Kimball, MPH, MD, Luigi Naldi, MD, Neil H. Shear, MD, Kavitha Goyal, MD, Steven Fakharzadeh, MD, PhD, Stephen Calabro, MS, Wayne Langholff, PhD, Yin You, MS, Claudia Galindo, MD, Seina Lee, MS, PharmD, Mark G. Lebwohl, MD  Journal of the American Academy of Dermatology  Volume 74, Issue 5, Pages e4 (May 2016) DOI: /j.jaad Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Psoriasis. Proportion of patients with Physician Global Assessment (PGA) score of 0 (clear) or 1 (minimal) at 6 and 12 months; patients initiating ustekinumab, infliximab, adalimumab, or etanercept on registry. Journal of the American Academy of Dermatology  , e4DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Psoriasis. Mean decrease in percentage of body surface area (%BSA) with psoriasis at 6 and 12 months; patients initiating ustekinumab, infliximab, adalimumab, or etanercept on registry. Journal of the American Academy of Dermatology  , e4DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Psoriasis. Proportion of patients achieving clinically meaningful improvement in Dermatology Life Quality Index (DLQI) score (≥5) by DLQI level (<10 and ≥10) at the time of initiating ustekinumab, infliximab, adalimumab, or etanercept on registry: 6 (A) and 12 (B) months. Journal of the American Academy of Dermatology  , e4DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Psoriasis. Proportions of patients achieving Dermatology Life Quality Index (DLQI) score of 0 or 1 (no impact on health-related quality of life) at baseline and at 6 and 12 months; patients initiating ustekinumab, infliximab, adalimumab, or etanercept on registry. Journal of the American Academy of Dermatology  , e4DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational."

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis  Juan Escalas, PhD, MD, Nicole Knöpfel, MD, Ana Martin-Santiago,

Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis  Juan Escalas, PhD, MD, Nicole Knöpfel, MD, Ana Martin-Santiago,
A girl with a solitary red bulla

A girl with a solitary red bulla
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review  Nolan J. Maloney, BS, Lisa D. Hisaw,

Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review  Nolan J. Maloney, BS, Lisa D. Hisaw,
Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States  Caroline P. Schaefer,

Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States  Caroline P. Schaefer,
Sarah Sung, MD, Alexa B. Kimball, MD, MPH 

Sarah Sung, MD, Alexa B. Kimball, MD, MPH 
Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
David T. Pompei, Pharm D, Kameron S. Rezzadeh, BS, Kate V

David T. Pompei, Pharm D, Kameron S. Rezzadeh, BS, Kate V
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry  David Fiorentino, MD, PhD, Vincent Ho, MD, Mark.

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry  David Fiorentino, MD, PhD, Vincent Ho, MD, Mark.
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,

Similar presentations

Ads by Google